We are excited to join Numinus, a true leader in mental health innovation. The combined entity is supported with over CA$50 million in pro-forma capital and positioned with distinct capabilities to serve a growing and diverse group of stakeholders. Novamind shareholders will receive Numinus common shares, listed on both the Toronto Stock Exchange and the OTC Markets Groups OTCQX, pursuant to the closing of the transaction. and Numinus' leadership in psychedelic-assisted psychotherapy in Canada creates a best-in-class company. The combination of Novamind's network of mental health clinics and research sites in the U.S. Yaron Conforti, CEO and co-founder, Novamind, stated, 'This transaction offers significant value for Novamind's shareholders and provides compelling new opportunities for our employees, patients and research partners. We look forward to welcoming the Novamind team to the Numinus family.'

Open this page to get detailed information about NM. After giving effect to the Transaction, Novamind Shareholders will hold 18 ownership in the pro-forma company (on a fully diluted in-the-money basis). NM.CN price, chart, market capitalization and other stock info about Novamind Inc. Our combined capabilities will deliver exceptional value for our clients, employees, and shareholders. The offer price represents a premium of 51 to Novaminds 20-day volume-weighted average price ('VWAP') on the Canadian Securities Exchange (the 'CSE') as of April 8, 2022. Summary of all time highs, changes and price drops for Novamind Historical stock prices Current Share Price: US0.20: 52 Week High: US1. The Novamind stock price may drop from 0.295 CAD to 0.000001 CAD. The company reported a 1M CAD gross margin on 2.1M of revenue in a year where foot traffic was drastically down in nearly every brick and mortar-based sector. Nyquvest continued: 'We expect this acquisition will significantly bolster our financial performance, growing Numinus' annual revenue to more than five times our current levels, and driving meaningful margin improvement through identified operating efficiencies. Licenses a key step in hosting contracted clinical trials for Schedule 1 controlled substances TORONTO, ON / ACCESSWIRE / Octo/ Novamind Inc. The Novamind stock price is 0.295 CAD today. While Field Trip is building its own clinics, Novamind is acquiring them purchasing Cedar Psychiatry’s 4 clinics for 3M CAD last year. market presence, complementary client programming and respected clinical research capabilities allow us to accelerate our strategic growth plans and broaden access to healing and wellness.' 'We prioritize working with the best partners in this industry and Novamind's U.S. Novaminds subsidiary, Cedar Clinical Research, to serve as a key clinical research siteTORONTO, ON / ACCESSWIRE / Ma/ Novamind Inc., (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ('Novamind' or. platform through eight established, reputable, efficiently operating and revenue-producing clinics,' stated Payton Nyquvest, founder and CEO, Numinus. The Novamind acquisition presents a transformational opportunity for Numinus to launch a strong U.S. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment. We believe our combined capabilities will deliver exceptional value for our clients, employees, and shareholders.”Īccording to Numinus, the acquisition is anticipated to generate C$3 million of annual cost savings “through the elimination of duplicate corporate expenses.'Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine. Payton Nyquvest, founder and CEO of Numinus, said in a press release: “We expect this acquisition will significantly bolster our financial performance, growing Numinus' annual revenue to more than five times our current levels, and driving meaningful margin improvement through identified operating efficiencies. On the side of the buyers, shareholders were urged to consider the issuance of 63,010,034 common shares to the security holders of Novamind.

This week both companies shared circulars with their shareholders, asking them to consider the acquisition.

That day, shareholders will vote in two special meetings on the proposed acquisition of Novamind by Numinus. This trading strategy invovles purchasing a stock just before the ex-dividend date in order to collect the dividend and then selling after the stock price has recovered. June 8, 2022 marks a turning point for both Numinus ( OTCQX: NUMIF) and Novamind ( OTCQB: NVMDF).